B

    BioCryst Pharmaceuticals Inc (BCRX)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $9.82
    -0.05 (-0.51%)

    Market Cap: $2.51B

    Last updated: Sep 01, 2026 at 4:59 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    68%(27/40)
    Avg Surprise
    +46.79%
    Streak
    6 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.12
    Range$0.11 - $0.12
    2 analysts
    EPS RevisionsNo revisions (7d)
    2
    0
    30d
    EPS Estimate Drift
    90d ago$0.10-8.7%
    60d ago$0.10-8.7%
    30d ago$0.10-8.7%
    7d ago$0.13+8.7%
    Current$0.12
    Revenue Consensus
    $166M
    Range$162M - $170M
    9 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.28
    Range$0.24 - $0.33
    2 analysts
    Revenue Consensus
    $202M
    Range$136M - $216M
    10 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.28---
    Sep 26EST
    		-$0.12---
    Jun 26
    Reported Aug 5
    		$0.30$0.14+114.29%Beat+650.0%
    Mar 26
    Reported May 6
    		$0.14$0.11+27.27%Beat+139900.0%
    Dec 25
    Reported Feb 26
    		$1.12$0.07+1500.00%Beat+961.5%
    Sep 25
    Reported Nov 3
    		$0.16$0.07+128.57%Beat+328.6%
    Jun 25
    Reported Aug 4
    		$0.04$0.03+33.33%Beat+166.7%
    Mar 25
    Reported May 5
    		$0.00N/A+100.20%Beat+100.1%
    Dec 24
    Reported Feb 24
    		$-0.13$-0.06-115.23%Miss+53.6%
    Sep 24
    Reported Nov 4
    		$-0.07$-0.08+12.50%Beat+63.2%
    Jun 24
    Reported Aug 5
    		$-0.06N/A+62.50%Beat+75.0%
    Mar 24
    Reported May 6
    		$-0.17$-0.23+26.09%Beat+39.3%
    Dec 23
    Reported Feb 26
    		$-0.28$-0.24-16.67%Miss+26.3%
    Sep 23
    Reported Nov 2
    		$-0.19$-0.19+0.00%Beat+17.4%
    Jun 23
    Reported Aug 3
    		$-0.24$-0.21-14.29%Miss+25.0%
    Mar 23
    Reported May 3
    		$-0.28$-0.29+3.45%Beat+30.0%
    Dec 22
    Reported Feb 21
    		$-0.38$-0.17-123.53%Miss-280.0%
    Sep 22
    Reported Nov 1
    		$-0.23$-0.26+11.54%Beat+30.3%
    Jun 22
    Reported Aug 4
    		$-0.32$-0.35+8.57%Beat-33.3%
    Mar 22
    Reported May 5
    		$-0.40$-0.40+0.00%Beat-11.1%
    Dec 21
    Reported Feb 23
    		$-0.10N/A+66.67%Beat+70.6%
    Sep 21
    Reported Nov 3
    		$-0.33$-0.29-13.79%Miss-26.9%
    Jun 21
    Reported Aug 5
    		$-0.24$-0.25+4.00%Beat+0.0%
    Mar 21
    Reported May 6
    		$-0.36$-0.27-33.33%Miss-50.0%
    Dec 20
    Reported Feb 25
    		$-0.34$-0.25-36.00%Miss-1600.0%
    Sep 20
    Reported Nov 5
    		$-0.26$-0.26+0.00%Beat+23.5%
    Jun 20
    Reported Aug 6
    		$-0.24$-0.25+4.00%Beat+29.4%
    Mar 20
    Reported May 6
    		$-0.24$-0.24+0.00%Beat+14.3%
    Dec 19
    Reported Mar 5
    		$-0.02N/A+92.59%Beat+92.0%
    Sep 19
    Reported Nov 6
    		$-0.34$-0.31-9.68%Miss-21.4%
    Jun 19
    Reported Aug 6
    		$-0.34$-0.32-6.25%Miss-78.9%
    Mar 19
    Reported May 8
    		$-0.28$-0.28+0.00%Beat-7.7%
    Dec 18
    Reported Mar 4
    		$-0.25$-0.25+0.00%Beat-25.0%
    Sep 18
    Reported Nov 6
    		$-0.28$-0.26-7.69%Miss-55.6%
    Jun 18
    Reported Aug 7
    		$-0.19$-0.24+20.83%Beat+9.5%
    Mar 18
    Reported May 8
    		$-0.26$-0.19-36.84%Miss-36.8%
    Dec 17
    Reported Feb 27
    		$-0.20$-0.15-33.33%Miss-233.3%
    Sep 17
    Reported Nov 7
    		$-0.18$-0.18+0.00%Beat-12.5%
    Jun 17
    Reported Aug 7
    		$-0.21$-0.19-10.53%Miss-
    Mar 17
    Reported May 4
    		$-0.19$-0.19+0.00%Beat-
    Dec 16
    Reported Feb 27
    		$-0.06N/A+73.91%Beat-
    Sep 16
    Reported Nov 7
    		$-0.16$-0.26+38.46%Beat-

    Key Metrics

    Valuation
    P/E Ratio5.71EV/EBITDA7.17x
    Price/FCF6.69xFCF Yield14.94%
    Profitability
    Profit Margin-40.90%Operating Margin45.10%
    ROE-1925.00%ROIC-599.57%
    Financial Health
    Debt/Equity-0.87xInterest Coverage3.67x
    Current Ratio2.32xQuick Ratio2.29x
    Trading Statistics
    Beta0.55Avg Volume3.21M
    52-Week High$11.2252-Week Low$6.00

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$9.79
    SMA 20$9.69
    SMA 50$9.70
    SMA 200$8.50
    EMA 10$9.79
    EMA 20$9.73
    EMA 50$9.57
    EMA 200$8.88

    MACD

    Line: 0.08Signal: 0.08Hist: -0.00

    ADX

    ADX: 16.3+DI: 22.7-DI: 18.7

    Aroon & PSAR

    Aroon Up52.0
    Aroon Down28.0
    PSAR$10.44

    Bollinger Bands

    Upper Band$10.54
    Lower Band$8.84
    %B Position1757%(Upper)
    Band Width0.57

    RSI (14-Day)

    Neutral
    52.3

    Momentum Oscillators

    Stoch %K37.7
    Stoch %D42.7
    Williams %R-70.5
    ROC (10d)0.8%
    Momentum0.08
    CCI (20d)36.0
    MFI (14d)47.4

    Volatility Measures

    ATR (14d)$0.41(4.2%)
    StdDev (20d)0.43
    Hist Vol47.4%(High)

    Volume Flow

    VWAP$9.83
    OBV-52.9M
    AD Line-25.3M
    CMF (20d)0.114

    Volume Metrics

    Avg Vol (20d)3.3M
    Vol Ratio0.8x
    VWMA (20d)$9.68

    Pivot Points

    R3$10.38
    R2$10.15
    R1$10.01
    Pivot Point$9.78
    S1$9.64
    S2$9.41
    S3$9.27

    Advanced Oscillators

    TSI4.65
    Ultimate Osc49.1
    KST24.52

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$218.25M$156.41M$406.56M$159.40M$163.35M$145.53M$131.53M$117.08M$109.33M$92.76M$93.40M$86.74M
    Cost of Revenue$3.84M$5.38M$9.52M$2.19M$2.80M$4.57M$6.09M$3.21M$1.70M$1.26M$1.56M$1.10M
    Gross Profit$214.41M$151.04M$397.03M$157.21M$160.56M$140.97M$125.44M$113.87M$107.63M$91.50M$91.84M$85.64M
    Operating Expenses$115.94M$852.63M$136.65M$127.62M$130.77M$119.74M$129.95M$106.18M$98.87M$105.98M$134.51M$97.56M
    R&D$51.97M$758.08M$40.87M$44.60M$43.39M$37.27M$49.44M$41.08M$37.62M$46.49M$70.05M$46.88M
    SG&A$63.98M$94.55M$95.78M$83.01M$87.38M$82.47M$80.51M$65.10M$61.25M$59.49M$64.56M$50.65M
    Operating Income$98.47M$-701,598,000$260.38M$29.59M$29.79M$21.23M$-4,508,000$7.69M$8.76M$-14,488,000$-42,670,000$-11,921,000
    Interest Income$2.46M$2.03M$2.77M$2.27M$2.45M$3.02M$3.22M$3.69M$3.47M$3.73M$4.09M$3.45M
    Interest Expense$21.71M$19.78M$24.56M$22.40M$25.75M$23.49M$24.45M$24.83M$24.73M$24.51M$24.58M$27.34M
    Income Before Tax$79.47M$-720,808,000$248.02M$12.13M$6.49M$758,000$-25,991,000$-13,447,000$-12,502,000$-35,014,000$-63,162,000$-35,819,000
    Income Tax Expense$1.08M$1.00M$2.17M$-769,000$1.40M$726,000$804,000$586,000$172,000$365,000$-1,431,000$330,000
    Net Income$78.39M$-721,812,000$245.84M$12.90M$5.08M$32,000$-26,795,000$-14,033,000$-12,674,000$-35,379,000$-61,731,000$-36,149,000
    EBITDA$98.82M$-701,748,000$259.69M$32.27M$29.42M$20.72M$-6,423,000$6.47M$-3,261,000$2.08M$-96,535,000$8.25M
    EBIT$98.72M$-703,060,000$260.38M$32.26M$29.79M$21.23M$-4,508,000$7.69M$8.76M$-14,488,000$-42,670,000$-11,921,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about BCRX

    Government Contracts

    Gov Obligations (TTM)
    $36032
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    100.1%
    Active Awards
    8
    New Awards (TTM)
    3
    Avg Remaining Term
    1.8 mo

    Top agency: Department of Veterans Affairs at 100.0% of trailing twelve month obligations across 1 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    36C26026F0006Department of Veterans AffairsDepartment of Veterans Affairs$360000Oct 1, 2025
    36C26026F0294Department of Veterans AffairsDepartment of Veterans Affairs$151465May 19, 2026
    36C24926F0152Department of Veterans AffairsDepartment of Veterans Affairs$30293May 21, 2026

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    BioCryst gets Japan approval for HAE drug in young children

    BioCryst Pharmaceuticals Inc. announced that Japan's Ministry of Health, Labor and Welfare has approved ORLADEYO (berotralstat) for prophylactic therapy in pediatric patients with hereditary angioedema (HAE) aged 2 to under 12 years. The approval is for a once-daily oral granule formulation and is based on interim results from the APeX-P clinical trial, showing consistent safety and tolerability. BioCryst plans to launch the drug in Japan after completing the reimbursement pricing process.

    Investing.com•8/25/26•
    Bullish

    BioCryst Pharmaceuticals Announces Japan Approval of ORLADEYO for Pediatric HAE Prophylaxis

    BioCryst Pharmaceuticals has received marketing approval in Japan for ORLADEYO (berotralstat) as the first oral prophylactic therapy for pediatric patients aged 2 to under 12 years with hereditary angioedema (HAE). This approval, based on positive interim results from the APeX-P clinical trial, offers a convenient granule formulation for children, reducing the burden of traditional injectable treatments. The company plans to launch the product in Japan after reimbursement processes and has also filed for approvals in Europe and Canada.

    Quiver Quantitative•8/25/26•
    Bullish

    Wall Street Analysts Think BioCryst (BCRX) Could Surge 117.96%: Read This Before Placing a Bet

    BioCryst Pharmaceuticals (BCRX) shares have gained 9.4% recently, with Wall Street analysts predicting a potential upside of 118%, reaching a mean target of $21.6. While analyst price targets can be misleading, strong agreement on earnings estimate revisions and a Zacks Rank #2 (Buy) suggest potential for upside. Investors are advised to be skeptical of price targets alone but consider the collective optimism regarding earnings.

    Eastern Progress•8/23/26•
    Bullish

    BioCryst Pharmaceuticals (BCRX), What Is Behind The Fresh Attention Now?

    BioCryst Pharmaceuticals (BCRX) has recently garnered attention, with its stock trading around $9.55. Despite a 27.33% year-to-date return, its five-year total shareholder return is down by 39.02%, indicating a recent turnaround. The company is considered undervalued with a narrative fair value of $21.30, primarily due to strong expectations for its rare disease drug ORLADEYO, though execution risks remain.

    Sahm•8/22/26•
    Somewhat-Bullish

    BioCryst Pharmaceuticals (NASDAQ:BCRX) Passes Minervini Trend Template and High-Growth Momentum Screen

    BioCryst Pharmaceuticals (NASDAQ:BCRX) has passed a dual screen combining Mark Minervini's Trend Template with a high-growth momentum filter, indicating it is in a strong uptrend with accelerating fundamentals. The stock exhibits robust technical indicators, trading above key moving averages and maintaining high relative strength, while also demonstrating significant EPS and revenue growth. Despite strong historical performance, investors are advised to consider risks such as potential negative revisions to forward-looking earnings estimates and to monitor price action and analyst forecasts.

    ChartMill•8/22/26•
    Bullish

    Frequently Asked Questions About BCRX

    Does BCRX pay dividends?
    BioCryst Pharmaceuticals Inc (BCRX) does not currently pay a regular dividend.
    What is BCRX's P/E ratio?
    BioCryst Pharmaceuticals Inc has a price-to-earnings (P/E) ratio of 5.71.
    What is BCRX's market cap?
    BioCryst Pharmaceuticals Inc (BCRX) has a market capitalization of $2.51B with a current stock price of $9.82.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In